Ains-The Wilms' tumour gene (WT1) product is expressed during the development of the urogenital system. This study was undertaken to evaluate four anti-WTl antibodies and use the most specific one to examine the expression of WTl in formalin fixed, paraffin wax embedded tissues from human embryos, fetuses, and paediatric renal neoplasms. Methods-The antibodies were assessed on paraffin sections of fetal kidney and by western blotting. Immunohistochemical techniques were optimised and performed on a range of embryonic, fetal, and infant tissues from 35 days post-conception to three months of age, and on a selection of paediatric renal neoplasms. Results-The antibodies tested were found to vary in their specificity. Anomalous expression in smooth muscle was seen with one batch of a commercial polyclonal antibody. WTl protein was detected in both the metanephros and the mesonephros, the spleen, the gonads, and in the peritoneal mesothelium in fetuses. WT1 was expressed in nuclei and was strongest in the podocytes of fetal kidney. The podocytes of infant glomeruli were also positive. There was focal positive staining in Wilms' tumours, nephrogenic rests, and in a cystic partially differentiated nephroblastoma. Staining of nuclei was seen in one of two rhabdoid tumours of the kidney. No positive staining was seen in other renal tumours.
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Conclusions-WTl is detected readily in formalin fixed material. There were differences in specificity between batches of the polyclonal antibodies used. The distribution of the WT1 gene product in tissues and tumours reflected previous findings with in situ hybridisation studies of WT1 mRNA. ( The Wilms' tumour gene, WT1, is located at lip13 and was identified after germline cytogenetic abnormalities were found at this site in patients with aniridia and Wilms' tumour.1 It acts as a tumour suppressor gene, and appears to be important in genitourinary development.2 WT 11 mRNA transcripts are expressed only in certain cells, mainly in the developing urinary tract,3 but also in mesothelial cells, Sertoli cells, granulosa cells, spinal cord, brain, and spleen. 4 The WT1 gene product is a 52-54 kDa nuclear protein that has four zinc fingers and acts as a transcriptional regulator, mainly as a repressor but sometimes as an activator.5 Its exact function is not clear, but it appears to be involved in the regulation of other growth factors including insulin-like growth factor 2 (IGF2), platelet derived growth factor, colony stimulating factor 1, insulin growth factor receptor, and retinoic acid receptor a genes. It also interacts with p53," appears to have a role in RNA processing, and is thought to act as an anti-oncogene in Wilms' tumour development.9 10 The main role of WT1 is in glomerulogenesis, where it appears to be involved in epithelial differentiation from blastema." The definitive kidney, the metanephros, develops from paraspinal metanephric mesenchyme by a complex interaction with the ureteric bud. The ureter develops from the distal end ofthe mesonephric duct.2 Blastema develops from metanephric mesenchyme; it condenses and develops into 'S' form nephrons, which then mature into glomeruli and proximal tubules. Glomerulogenesis ceases at about 36 weeks of gestation and blastema is usually not seen after this time.
Although cytogenetic abnormalities of the The recent availability of antibodies to the WT1 gene product for use with formalin fixed material prompted this systematic study of the specificity of these antibodies and the expression of WT1 in the major organs of developing embryos and fetuses from 35 days postconception until term, and in paediatric tumours. These tumours included Wilms' tumour, cystic partially differentiated nephroblastoma, nephrogenic rests, mesoblastic nephroma, malignant rhabdoid tumour of the kidney, clear cell sarcoma of the kidney, renal cell carcinoma, and adrenal neuroblastoma. Neuroblastomas were examined as they can be clinically difficult to distinguish from primary renal tumours, and may present as an intrarenal tumour. Our purpose was to document WVlT1 gene expression in the normal developing kidney, and in renal tumours, and to see whether it was diagnostically useful in the differential diagnosis of paediatric renal tumours.
In the light of initial studies a further selection of non-renal tumours, derived from tissues found positive for WT1 in fetuses, was examined also.
Materials and methods
Two batches of commercial antibody directed against the WT1 protein, WT C19 (Santa Cruz, California, USA; catalogue number sc-192, batches 6063 and D124), and two antibodies produced by immunising rabbits with the WT1 fusion protein available in the Cancer and Leukaemia in Childhood funded laboratory, University of Bristol were assessed. All were polyclonal antibodies raised in rabbits.
Formalin fixed, paraffin wax embedded kidney from an 18 week fetus was used in the initial assessment of the specificity of each antibody.
Western blotting was performed using WT1 protein obtained from an adenovirus transformed human fetal kidney line T5A1 22 This is derived from a 293 cell line with inducible WT1 expression following transfection with a metallothionine inducible vector (pMEP4).
Postmortem and surgical tissues came from the files of the department of paediatric pathology, Bristol Children's Hospital. Parental consent had been given for using postmortem tissues for research. Serial sections from two well preserved embryos of 35 and 43 days post-conceptional age were selected to include the genitourinary ridge. Sections from a male and a female well preserved normal fetus of [12] [13] weeks, 17-18 weeks, 24-25 weeks, and 38-40 weeks gestational age were chosen to include all major organs. Kidneys from two infants (three months old) were also examined.
Thirty one paediatric renal tumours were chosen to include 14 Wilms' tumours (13 renal and one extrarenal) one with focal anaplasia, one cystic partially differentiated nephroblastoma, six nephrogenic rests, four mesoblastic nephromas, two malignant rhabdoid tumours of the kidney, two clear cell sarcomas of the kidney, and two renal cell carcinomas. Two of the Wilms' tumours were later rejected because of insufficient viable tumour and in another case a nephrogenic rest was no longer present in recut sections tested.
In the light of the initial results several examples of tumour types thought to arise from tissues that were positive for WT1 in fetuses were studied. These were three adenomatoid Cl 9 showing that the WTI band is clearly increased in the induced 7 column, 4) compared with the non-induced TSA 1 (first column, 3). This antil to be more specific. tumours, three granulosa cell tuw ovarian mucinous cystadenoma, an racic mesotheliomas.
The tissues were all formalin fi essed into paraffin wax, sectioned placed on 3-amino-propyltriet (APES) coated slides and baked for . hour at 60°C. The immunohisi method was optimised by varying th time of microwave antigen retrieval 1 rate buffer (2.1 g citric acid in disti pH 6.0). Slides were placed in covered tray, heated on high power, a up with distilled water after 2C Antibodies were titrated with s normal fetal kidney using the av method and peroxidase with diamin4
(DAB) as the detection system. The optimal dilution for the C19 antibody was 1/1000 in phosphate buffered saline. An 18 week fetal kidney was used as a positive control in each run. A duplicate slide of each case omitting the primary antibody was processed as a negative control. Only nuclear staining was scored positively. Cytoplasmic staining sometimes seen in mature proximal tubules was regarded as an artefact due to incompletely blocked endogenous peroxidase, and was present in the negative control sections.
Results

IMMUNOHISTOCHEMICAL ASSESSMENT OF THE FOUR ANTIBODIES ON FETAL KIDNEY
The best results were obtained using the two batches of commercial antibody (Santa Cruz). Although reasonable results had been obtained previously on frozen sections using the other antibodies, these produced a high background signal on paraffin wax embedded sections. after 36 weeks' gestation when nephrogenesis has ceased, and staining was seen in normal glomeruli in the kidney adjacent to the renal tumours in surgical specimens. Staining was weak in the infant kidneys .
Gonads
The ovaries showed staining in granulosa cells, although it was generally weak and only seen strongly in the youngest fetuses ( fig 2C) . Testis from a 25 week fetus showed weak staining of immature Sertoli cells. No germ cell staining was seen. The embryos had strong staining of gonadal stromal cells, but the sex was not known.
Spleen
Staining of stromal and possible haemopoetic cells was seen, but only in the 18 week fetuses. The spleen was not present on the recut sections of the 12 week fetuses and no staining was seen in the older fetuses.
Mesothelium
There was positive staining of the mesothelium in the embryos and the youngest fetuses, most prominently in the mesothelium overlying the developing gonad and spleen, and in the pelvis. There was also some focal staining of the visceral pleural mesothelium.
Decidua
Staining was seen in a few cases in decidual cells in the decidua basalis ( fig 2D) .
Other organs Some positive stromal cell nuclei were seen in the uterus of an 18 week fetus. No staining was seen in any of the other organs including lungs, heart, bowel, liver, pancreas, thyroid, adrenal glands, thymus, muscle, and placenta. Choroid plexus, ependyma and spinal cord were also negative. A parasagittal section of one embryo showed no staining of the mesenchymal tissues between developing nerve trunks.
Renal tumours
Results are summarised in table 2. The tumours that were positive included most of the Wilms' tumours, the cystic partially differentiated nephroblastoma, and the perilobar nephrogenic rests. One of the two rhabdoid tumours was positive. All of the other paediatric renal tumours, including all four mesoblastic nephromas, both clear cell sarcomas, and Table 2 Expression of the WTI protein in paediatric renal tumours as assessed by the C19 antibody the two neuroblastomas were negative. Adjacent kidney, if present, showed staining of the podocytes, forming an internal positive control.
The pattern of staining in the Wilms' tumours varied from one case to another. Some tumours showing glomerulogenesis often had a staining pattern similar to that in fetal kidneys ( fig 2E) . Others showed zones of positivity in the blastema. Glomeruloid structures were usually positive. Some tumours had extensive tubule formation, and again these were variably positive, some tubules showing an abrupt transition from positive to negative staining reminiscent of the abrupt change in the parietal cells of the glomerulus and the proximal tubule ( fig 2F) . The stroma was always negative. One tumour with focal anaplasia was negative in the areas of anaplasia. One of the two Wilms' tumours that showed no positive staining was from a child with WAGR syndrome; the associated intralobar rest was also negative. The other Wilms' tumour that stained negatively was from an apparently normal child. Uninvolved kidney in the same sections from both cases showed normal staining.
Other tumours that showed some positive staining for WT1 included the microscopic perilobar nephrogenic rests and the cystic partially differentiated nephroblastoma. These tumours are thought to be closely related to Wilms' tumours and contain blastema.
One of two rhabdoid tumours showed focal positive staining of their nuclei. No expression of WT1 was found in the clear cell sarcomas of the kidney or the mesoblastic nephromas.
Non-renal tumours
No staining was seen in the three granulosa cell tumours of the ovary examined, or two thoracic mesotheliomas. Three adenomatoid tumours showed at least focal positivity, as did an ovarian mucinous cystadenoma. Discussion Using immunohistochemistry, this study has examined both a wide range of fetal tissues at different gestational ages, and a variety of tumours, for WT1 protein expression. The pattern of expression of WfT1 found in fetal kidney supports previous observations,3 4 and is present throughout glomerulogenesis. Staining of podocytes in mature glomeruli suggests that WT1 has an important function in maintaining glomerular function, and presumably defective WT1 protein is a factor in the pathogenesis of the glomerulopathy in Drash syndrome.
The study demonstrates that some batches of commercial polyclonal antibodies give significant differences in staining: muscle staining seen with one batch of antibody was not seen with another batch. Although muscle staining has been described in another study'5 that also used an antibody from Santa Cruz, mRNA for WT1 has not clearly been demonstrated by in situ hybridisation techniques in muscle, although expression in the somites of vertebrate embryos has suggested a role for WT1 in smooth, cardiac, and skeletal muscle development.23 In contrast, muscle differentiation in Wilms' tumours is associated with WT1 mutations. 24 Ramani and Cowell found that the positive staining in muscle was blocked by pretreatment with the immunising peptide,'5 suggesting that muscle may have a nuclear protein with a similar epitope to WT1.
The staining pattern in the tumours was in agreement with previous studies.' 4 The pattern found in Wilms' tumours generally recapitulated the pattern of expression found in the fetal kidney. Some areas of blastema, particularly adjacent to the stroma or epithelium, often showed positive staining. Not all epithelial structures were positive and the sudden transition of some tubules appeared to be similar to the transition between expression of WT1 in the Bowman's capsule and absence of WT1 in the proximal tubules. No positive staining was seen in the stroma of the tumours.
One of the two Wilms' tumours that showed no staining was from a patient with WAGR syndrome and a cytogenetic deletion at l 1p3 Following these initial results some other tumours thought to arise from tissues that were positive in the fetuses or embryos were examined for WT1 expression. A mucinous cystadenoma of the ovary and two adenomatoid tumours (of the uterus and Fallopian tube, respectively) showed focal positive staining. We had found strong expression of WT 1, as assessed by immunohistochemistry, in the mesothelium of the pelvis in embryos, and both of these tumours are thought to be derived from mesothelium. Two thoracic malignant mesotheliomas from adults were negative, but a recent paper examining mesotheliomas has demonstrated that WT1 may be useful in identifying these tumours. 
